Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Cha5.2
Chamomile – Forschung
Überwiegend Mechanismus / Beobachtung
14 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Chamomile sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 80 Teilnehmenden.
Basierend auf 14 Studien · 6 Meta-Analysen · 4 RCTs · 3,223 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Anxiety & stressMögliche Verringerung der Symptome einer generalisierten Angststörung, die Evidenzlage ist jedoch uneinheitlich (eine positive RCT; eine größere Netzwerk-Metaanalyse fand keinen Unterschied zu Placebo) · 2-8 Wochen
For clinical studies, meta-analyses were conducted using Stata, and a random-effects model was used to estimate effect sizes.
Moreover, the pooled analysis of three eligible human studies demonstrated no statistically significant effect of Chamomile on serum testosterone levels (ES = 5.05, 95% CI = (-1.38, 11.49), p = 0.124).
Overall, animal studies have demonstrated the potential benefits of Chamomile consumption in the treatment of PCOS, possibly through anti-androgenic, anti-inflammatory, analgesic, and antioxidant effects.
Conclusions Chamomile may be a promising alternative for pain management due to its potential analgesic effect and lack of significant difference compared to other pain medication; however, more research is needed.
Ahmadi M, Mozaffarpur SA, Shirafkan H. · Caspian journal of internal medicine (2025)
The findings suggest a potential analgesic effect of chamomile compared to placebo.
Additionally, no significant difference was found between chamomile and other pain medication.
The studies included in this review, however, exhibited significant heterogeneity.
5Systematische Übersichtn=2,896 · very large study2025
Furthermore, there is insufficient data regarding its safety during pregnancy and lactation.
Ostovar M, Rezaee Z, Najibi SM, Hashempur MH. · Complementary therapies in medicine (2025)
No allergic adverse events were reported in the clinical trials; however, among the eleven case reports, six reported adverse events associated with allergic reactions to chamomile, ranging from anaphylactic reactions (in three patients) to short-lasting acute rhinitis.
Conclusions In conclusion, data extracted from clinical trials and published case reports suggest that chamomile is generally safe when used in controlled dosages, with self-limiting minor adverse events.
However, case reports indicate that allergic reactions should be taken into consideration.
The mean difference, confidence intervals, and standard error from the extracted means and standard deviations for relevant outcomes were calculated.
Statistical tests from the meta-analysis demonstrated that chamomile exhibited statistically significant reductions in mucositis severity and pain level, indicating the anti-inflammatory effects of chamomile.
Conclusion This study highlights chamomile's potential as a natural alternative for managing inflammation and microbial infections, offering a promising alternative to standard treatments.
There was insufficient evidence to confirm the effectiveness of Valerian in standard-controlled estimation or the ineffectiveness of Chamomile (MD: 0.54, 95% CrI: -5.13 to 6.25) compared with a placebo for anxiety.
Zhang W et al. · Pharmacological research (2022)
Chamomile was not significantly different from placebo for anxiety (MD 0.54, 95% CrI -5.13 to 6.25)
Bayesian network meta-analysis of 29 trials across 12 herbs; indirect comparisons used
Evidence considered preliminary given small sample sizes
Clinician-guideline nutraceutical review assessed chamomile among agents for psychiatric symptoms.
Sarris J et al. · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2022)
Chamomile assessed for generalised anxiety disorder
Given a '+/-' (Not Currently Recommended) rating for GAD due to mixed evidence
Part of broader WFSBP/CANMAT nutraceutical and phytoceutical guidance
Further research is necessary to optimize dosage and mitigate adverse reactions for safer and more effective management of menopausal symptoms.
Mohsenzadeh-Ledari F, Agajani Delavar M, Moghadamnia AA, Khafri S, Bekhradi R, Behmanesh F, Yazdani S. · Menopause (New York, N.Y.) (2025)
In a triple-blind clinical trial with 80 postmenopausal women (aged 47-62) from Babol City Health Center, participants were randomly assigned to receive either chamomile (100 mg capsules with 1.2% apigenin, four times daily) or a placebo over 12 weeks.
Results Notable differences were found between the intervention and control groups in the overall scores on the symptom scorecard from baseline to 12 weeks' postintervention (-10.36; 95% confidence interval [CI], -13.84 to -6.92; P < 0.001).
Specific subscores also improved in the intervention group: vasomotor (-2.25; 95% CI, -3.09 to -1.42; P < 0.001), psychological (-3.74; 95% CI, -5.29 to -2.20; P < 0.001), locomotor (-2.70; 95% CI, -3.63 to -1.77; P < 0.001), and urological (-1.89; 95% CI, -2.77 to -1.00; P < 0.001).